Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio (oral nalbuphine ER), an investigational therapy for the treatment of chronic cough. The company is developing this therapy for patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio acts on the cough reflex arc centrally and peripherally as a kappa receptor agonist and a mu receptor antagonist. The company has completed Phase 2 trials for IPF-related and refractory chronic cough and plans to initiate Phase 3 trials in the United States and Phase 2b trials in the United Kingdom, Canada, and other European countries. Trevi Therapeutics retains worldwide commercial rights for Haduvio and was founded in 2011.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage trevitherapeutics.com
Sector Healthcare IR page ir.trevitherapeutics.com
Tags
chronic cough, idiopathic pulmonary fibrosis, interstitial lung disease, refractory chronic cough, opioid receptor modulation, kappa agonist, mu antagonist, clinical-stage, respiratory diseases, pulmonary fibrosis, Haduvio, nalbuphine ER, CORAL trial, RIVER trial
Press page —

Metrics

Valuation  
Market cap $ 2.041B
Market cap (USD) $ 2.041B
P/E -36.72
PEG —
P/BV 6.74
P/S —
P/OCF -33.22
P/FCF -48.48
Dividend yield —
Turnover / mcap —
Returns  
ROE -30.2%
ROI -25.9%
ROIC -22.5%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 19
Quality score -83.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Assets 193.439M 110.9M 89.403M 123.015M 38.475M 47.131M 60.001M 10.526M
Net profit -42.759M -47.911M -29.065M -29.152M -33.94M -32.758M -26.05M -20.545M
Free cash flow -42.101M -38.291M -31.847M -28.334M -28.946M -29.032M -23.102M -18.447M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 12.52 4.12 1.34 1.93 0.78 2.42 3.75 —
Price performance 12m 2.04 2.07 -0.31 1.47 -0.68 -0.35 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 46,000 356,000 257,000 144,000 27,000 1.34M 1.03M 753,000
Cash and deposits (USD) 22M 7.2M 57.3M 45M 36.8M 12.6M 32.4M 34.1M 18.9M
Right-of-use assets (USD) — 379,000 312,000 227,000 131,000 24,000 1.14M 915,000 677,000
Cash flow detail
Operating cash flow (USD) — -18.3M -23.1M -29M -28.9M -28.2M -31.7M -38.3M -42.1M
Purchases of property, plant and equipment (USD) — -158,000 -9,000 -32,000 — -159,000 -137,000 -35,000 -12,000
Change in receivables (cash effect) (USD) — -135,000 -374,000 — — — — — —
Change in payables (cash effect) (USD) — 66,000 777,000 417,000 831,000 9,000 -1.05M 1.61M -598,000
Interest paid (cash effect) (USD) — -152,000 — -180,000 -603,000 -594,000 -331,000 -4,000 —
Income taxes paid (cash effect) (USD) — — — — — — — 32,000 33,000
Share-based compensation (USD) — 496,000 1.13M 2.42M 2.54M 2.33M 2.25M 3.59M 5.19M
Operating cash flow before change in receivables (USD) — -18.2M -22.7M — — — — — —
Free cash flow (OCF - PPE - intangibles) (USD) — -18.4M -23.1M -29M — -28.3M -31.8M -38.3M -42.1M
Income detail
Research and development expense (USD) — 14.1M 19.3M 22.3M 23M 19.8M 23.7M 39.4M 33.5M
↳ 5y CAGR +11.0% +15.3% +8.4%
Total comprehensive income (USD) — — — — -33.9M -29.3M -29M -47.8M -42.7M
Comprehensive income to owners (USD) — — — — -33.9M -29.3M -29M -47.8M -42.7M
Reported Jun 14, 2019 Mar 16, 2020 Mar 16, 2020 Mar 25, 2021 Mar 16, 2023 Mar 16, 2023 Mar 20, 2024 Mar 17, 2026 Mar 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting

Positive meeting with the FDA on the non-IPF ILD-related chronic cough program held in October 2026; Phase 2 dose-ranging trial expected to initiate in the first quarter of 2027

Notice of Allowance from the USPTO for patent application covering nalbuphine ER dosing in hepatically impaired patients with non-IPF ILD-related chronic cough, with patent expected to expire in 2041

Cash runway into 2030 funding key clinical milestones

Management to host a conference call and webcast today at 4:30 p.m. ET

New Haven, Conn., November 9, 2026 – Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced financial results for the quarter ended September 30, 2026, and provided business updates.

November 2, 2026

PDF Version

Conference call and webcast to be held at 4:30 p.m. ET

NEW HAVEN, Conn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Monday, November 9, 2026, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended September 30, 2026.

Conference Call and Webcast To register for the live conference call and webcast, please visit the ‘Investors & News’ section of the Company’s website or access directly at ir.trevitherapeutics.com/news-events/events. Please note for phone participants: Once registered, you will receive an email with unique call-in details. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). In clinical trials, Haduvio showed a statistically-significant reduction in cough frequency, consistent across baseline cough frequencies and showed improvements in patient-reported outcomes, in both patients with IPF-related chronic cough and in patients with RCC. Haduvio is believed to act on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.

Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.

RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.

The FDA has conditionally accepted Haduvio as the trade name for nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

October 27, 2026

PDF Version

Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET

NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and David Hastings, Chief Financial Officer, will participate in a fireside chat at the Stifel 2026 Healthcare Conference on Wednesday, November 11, at 10:00 a.m. ET. The conference will be held from November 10-12 in New York, and Ms. Good and Mr. Hastings will also participate in investor meetings with attendees.

To register for the fireside chat virtually, click here.

About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). In clinical trials, Haduvio showed a statistically-significant reduction in cough frequency, consistent across baseline cough frequencies, and showed improvements in patient-reported outcomes, in both patients with IPF-related chronic cough and in patients with RCC. Haduvio is believed to act on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.

Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.

RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.

The FDA has conditionally approved Haduvio as the trade name for nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

Prompts

Trevi Therapeutics, Inc. (ticker TRVI), listed in United States.

ETFs Holding Trevi Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
LFSC 2.59% 196,667 $ 3.265M Aug 31, 2026
VFMO 0.13% 146,689 $ 2.435M Aug 31, 2026
FESM 0.04% 112,852 $ 2.105M Jun 30, 2026
MSSM 0.01% 3,626 $ 60.192K Aug 31, 2026
DFAS 0.00% 16 $ 217.92 Nov 12, 2026